摘要
目的 探讨平均血小板体积/淋巴细胞比值(MPVLR)对PD-1抑制剂联合恩度治疗晚期非小细胞肺癌(NSCLC)预后的评估价值。方法 选取接受PD-1抑制剂联合恩度治疗的晚期NSCLC患者75例,根据预后分为预后良好组(52例)和预后不良组(23例);根据MPVLR截断值分为MPVLR低值组(45例)和MPVLR高值组(30例)。比较各组患者基线资料、MPVLR水平和预后情况。多因素COX回归分析预后的影响因素,ROC曲线分析MPVLR对患者预后的预测价值。结果 预后良好组和预后不良组患者的TNM分期、KPS评分、东部肿瘤协作组评分、转移部位个数、治疗线数、MPVLR对比,差异具有统计学意义(P<0.05)。预后不良组患者的MPVLR水平高于预后良好组(P<0.05)。MPVLR高值组无进展生存期低于MPVLR低值组(P<0.001)。转移部位个数≥3个、治疗线数为三线及以上、MPVLR>5.319均是患者预后的危险因素(P<0.05)。MPVLR对患者预后具有良好的预测价值(P<0.05)。结论 MPVLR对PD-1抑制剂联合恩度治疗晚期NSCLC患者预后具有良好的评估价值。
Aim To explore the evaluation value of mean platelet volume to lymphocyte ratio(MPVLR) in predicting the prognosis of advanced non-small cell lung cancer(NSCLC) treated with PD-1 inhibitor combined with Endostar.Methods A total of 75 patients with advanced NSCLC treated with PD-1 inhibitor combined with Endostar were selected and divided into a good prognosis group(52 cases) and a poor prognosis group(23 cases) based on prognosis.According to the MPVLR cutoff value,patients were further divided into a low MPVLR group(45 cases) and a high MPVLR group(30 cases).Baseline data,MPVLR levels,and prognosis were compared between groups.Multivariate COX regression analysis was used to identify factors affecting prognosis,and ROC curve analysis was performed to evaluate the predictive value of MPVLR for patient prognosis.Results There were significant differences in TNM stage,KPS score,eastern cooperative oncology group score,number of metastatic sites,treatment lines,and MPVLR between the good prognosis group and the poor prognosis group(P<0.05).The MPVLR level in the poor prognosis group was higher than that in the good prognosis group(P<0.05).The progression free survival in the high MPVLR group was lower than that in the low MPVLR group(P<0.001).The number of metastatic sites ≥3,treatment lines ≥3,and MPVLR>5.319,were all risk factors for patient prognosis(P<0.05).MPVLR had a good predictive value for patient prognosis(P<0.05).ConclusionMPVLR has a good evaluation value in predicting the prognosis of advanced NSCLC patients treated with PD-1 inhibitor combined with Endostar.
作者
贾同磊
许艳辉
曹新超
贺丽君
马平
JIA Tonglei;XU Yanhui;CAO Xinchao;HE Lijun;MA Ping(Department of Pulmonary Diseases,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Cangzhou 061000,Hebei,China;Department of Thoracic Surgery,Cangzhou People's Hospital,Cangzhou 061002,Hebei,China)
出处
《中南医学科学杂志》
2025年第2期272-275,共4页
Medical Science Journal of Central South China
基金
河北省医学科学研究项目(20242172)。
